Table 3 ALDH1 expression and associations with basal markers, molecular subtypes, BMI-1, c-kit and p63 expression

From: Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer

Variable

ALDH1 negative ( n; %); n =95

ALDH1 positive ( n; %); n =88

OR (95% CI)

P -value

CK 5/6

 Negative

86 (56)

68 (44)

1.0

 

 Positive

8 (29)

20 (71)

3.2 (1.3–7.6)

0.008

P-cadherin

 Negative

75 (56)

58 (44)

1.0

 

 Positive

20 (40)

30 (60)

1.9 (1.0–3.8)

0.048

EGFR

 Negative

81 (56)

64 (44)

1.0

 

 Positive

12 (33)

24 (67)

2.5 (1.1–5.4)

0.015

BLP1

 Absent

86 (56)

69 (44)

1.0

 

 Present

8 (30)

19 (70)

2.9 (1.2–7.4)

0.013

BLP2

 Absent

80 (56)

62 (44)

1.0

 

 Present

15 (37)

26 (63)

2.2 (1.1–4.6)

0.026

BLP3

 Absent

84 (56)

67 (44)

1.0

 

 Present

10 (32)

21 (68)

2.6 (1.2–6.0)

0.018

BLP4 (CBP)

 Absent

80 (57)

61 (43)

1

 

 Present

14 (34)

27 (66)

2.5 (1.2–5.2)

0.011

BLP5

 Absent

77 (58)

56 (42)

1.0

 

 Present

17 (35)

32 (65)

2.6 (1.3–5.1)

0.005

TNP

 No

65 (61)

41 (39)

1.0

 

 Yes

30 (39)

47 (61)

2.5 (1.4–4.5)

0.003

Molecular subtype

 Luminal

56 (68)

27 (32)

1.0

 

 HER2

8 (36)

14 (64)

3.6 (1.4–9.7)

0.008

 Basal-like

14 (34)

27 (66)

4.0 (1.8–8.8)

0.000

 Unclassified

16 (44)

20 (56)

2.6 (1.2–5.8)

0.018

c-kit

 Negative

91 (52)

84 (48)

1.0

 

 Positive

4 (50)

4 (50)

1.1 (0.3–4.4)

NS

p63

 Negative

80 (53)

71 (47)

1.0

 

 Positive

15 (47)

17 (53)

1.3 (0.6–2.7)

NS

BMI-1

 Negative

64 (46)

74 (54)

1.0

 

 Positive

31 (69)

14 (31)

0.4 (0.2–0.8)

0.009

  1. Abbreviations: ALDH1=aldehyde dehydrogenase 1; OR=odds ratio; CI=confidence interval; NS=not significant; EGFR=epidermal growth factor receptor; CK=cytokeratin; CBP=core basal phenotype; TNP=triple-negative phenotype.